US Stock Market Closed

Dashboard

Regeneron Pharmaceuticals, Inc. (REGN)

bolt HIT FAIR VALUE

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

B

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

S

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

CEO

Leonard S. Schleifer

Employees

8,100

Industry

Ophthalmology Biopharmaceuticals

Sector

Healthcare

Headquarters

Tarrytown

Exchange

NASDAQ

Summary Stats

Market Cap

80.4B

Revenue

13.7B

Net Income

5.37B

EPS

$47.37

Price-to-Earnings

15.86

Price-to-Book

3.75

Debt-to-Equity

0.29

News

Analyst Ratings

Price targets projected by 22 analysts

High

$793.00

Average

$673.86

Low

$550.00

Ratings calculated by 26 analysts

Buy

15

Hold

11

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2022

Last Earnings

Above by $2.53

Actual

$12.56 +25.2%

Consensus

10.03

Report Date

Year Ago

23.72

Year Ago Change %

Down 47%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites